论文部分内容阅读
对７３例慢性乙型肝炎患者随机分为两组，即异体ＬＡＫ细胞联合ＩＬ－２治疗组４８例和一般护肝药物对照组２５例。在治疗前及治疗后一个月检测乙型肝炎病毒ＤＮＡ，两对半血清ＨＢＶ标志物、肝功能等项目。结果显示治疗组ＨＢｅＡｇ阴转率为６０．４％（Ｐ＜０．０１），ＨＢｃＡｇ、抗ＨＢｃ－ＩｇＭ及ＨＢＶＤＮＡ的阴转率分别为３７．５％、２９．２％和４１．７％（Ｐ＜０．０５）。ＨＢｓＡｇ阴转率为６．３％与对照组无显著性差异（Ｐ＞０．０５）。治疗组肝功能恢复效果较对照组佳。
73 patients with chronic hepatitis B were randomly divided into two groups, namely, allogeneic LAK cells combined IL-2 treatment group 48 cases and general liver protection drug control group 25 cases. Hepatitis B virus DNA, two pairs of serum half-serum HBV markers and liver function were tested before treatment and one month after treatment. The results showed that the negative conversion rate of HBeAg in treatment group was 60.4% (P <0.01), and the negative conversion rates of HBcAg, anti-HBc-IgM and HBVDNA were 37.5%, 29.2% and 41.7% P <0.05). The rate of negative conversion of HBsAg was 6.3% and there was no significant difference between the two groups (P> 0.05). The treatment group liver function recovery better than the control group.